Opendata, web and dolomites

Quality2Cells

TimeLapseReader for Quality Control of Immune Cells used for Cell-Based Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Quality2Cells project word cloud

Explore the words cloud of the Quality2Cells project. It provides you a very rough idea of what is the project "Quality2Cells" about.

thousands    strategy    medical    bench    cure    tumours    manufacturing    entry    cells    treatment    automated    personalized    remaining    strives    disruptive    treat    ready    final    difficult    feasibility    culture    carriers    reproducible    millions    setting    live    plan    hundred    facilities    standardized    therapeutic    complete    ce    migrating    identification    qc    device    cell    freedom    enter    cancer    types    migration    provider    combination    reagents    player    instrument    innovation    therapy    quality    explore    tests    cured    ibidi    timelapsereader    assuming    global    transform    worldwide    15    efficient    regarding    business    approval    patients    motility    marking    medicine    serval    20    immune    assays    solution    consolidate    adverse    validate    ctb    eminent    cbt    competitor    market    expensive    patient    actively    risks    slides    inactive    elicit    kits    regulatory    standard    obtain    operate    version   

Project "Quality2Cells" data sheet

The following table provides information about the project.

Coordinator
IBIDI GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG MARTINSRIED
postcode: 82152
website: www.ibidi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.ibidi.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBIDI GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine. However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks. In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects. Yet, there is no quality control (QC) regarding motility of therapeutic cells before patient treatment. The goal of the proposal is to promote an integrated bench-top instrument for reliable assessment of motility parameters in standardized cell culture carriers, i.e. the TimeLapseReader.

As leading provider of live cell migration assays ibidi strives to market a complete QC solution based on an automated instrument in combination with ready-to-use QC kits, slides and reagents. The TimeLapseReader will allow robust and reproducible migration tests in manufacturing facilities and set a new standard for QC of immune cell in CBT.

In Phase 1 the feasibility study will explore key parameters for QC in the most relevant therapeutic cell types and the best market entry strategy. Objectives include: • Identification of relevant QC parameters for therapeutic cells. • Setting up the business plan including competitor and freedom-to-operate analysis. • Strategy to obtain regulatory approval / CE-Marking for the final device version.

Expected impact is eminent as CBT is going to enter the medical market with serval hundred to thousands of patients treated worldwide per year. It is expected, that up to 20% of all cancer patients can be cured with CTB within 10-15 years assuming serval millions QC per year. ibidi will apply for funding to validate QC tests in a Phase 2 proposal. Phase 2 will consolidate the technology and transform ibidi into a global player of medical QC in the CBT field.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUALITY2CELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUALITY2CELLS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More